Development of novel agents based on nitric oxide for the control of colon cancer.
Nitric oxide-donating nonsteroidal anti-inflammatory drugs (NO-NSAIDs) represent a novel class of compounds that hold promise as agents for the control of colon cancer. They are derivatives of conventional NSAIDs that have been modified by adding to them, via a spacer molecule, a nitric oxide releasing moiety. The expectation is that the combined effects of NO and the NSAID moiety will exceed those of each structural component alone. Extensive work has demonstrated their potency and efficacy in preclinical models of colon cancer. The mechanism of action of NO-NSAIDs involves the modulation of several critical cellular signaling pathways, whereas the induction of a state of oxidative stress, at least by NO-aspirin, appears to be a major proximal event. Clinical trials are needed to assess the role of NO-NSAIDs in the control of colon cancer.
Kozoni
Vassiliki
V
Division of Cancer Prevention, Stony Brook University, Stony Brook, NY 11794-5200, USA.
Rosenberg
Theophilos
T
Rigas
Basil
B
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry* / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000737:chemistry / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000737:chemistry / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D020030:Nitric Oxide Donors; D009569:Nitric Oxide